MLL MUNCHNER LEUKAMIELABOR GMBH

Their core work

MLL Munich Leukemia Laboratory is a specialized private diagnostic laboratory focused on the molecular genetics and diagnostics of blood cancers (leukemia, lymphoma, myelodysplastic syndromes, multiple myeloma). They contribute real-world patient data, molecular profiling, and hematological expertise to large European research consortia. Their work bridges clinical diagnostics with translational research, providing the data infrastructure and domain knowledge needed to advance personalized medicine in hematology. As an SME, they operate at the intersection of routine clinical diagnostics and research-grade genomic analysis.

What they specialise in

How they've shifted over time

MLL's early H2020 work (2017-2020) centered on building large-scale real-world data platforms for blood cancers — aggregating clinical and outcome data across hematological malignancy subtypes through HARMONY and HARMONY PLUS. From 2021 onward, their focus shifted decisively toward high-resolution molecular methods: multi-omics, federated learning, epigenetic regulation, and single-cell sequencing (GenoMed4ALL, INTERCEPT-MDS). The trajectory shows a clear move from population-level data collection to mechanistic, single-cell and AI-driven precision medicine.

MLL is moving from broad hematological data aggregation toward molecular-resolution and AI-driven approaches, positioning them for next-generation precision diagnostics in blood cancers.

How they like to work

MLL operates exclusively as a participant, never as coordinator — they bring specialized diagnostic data and hematological expertise to consortia led by others. They work in large networks (89 unique partners across 17 countries), indicating comfort in big, multi-stakeholder EU projects. This pattern suggests they are a trusted domain contributor that consortia actively recruit for their data assets and diagnostic capabilities rather than a project management-oriented organization.

MLL has collaborated with 89 unique partners across 17 countries, built primarily through large hematology-focused consortia like HARMONY. Their network spans most of Europe, reflecting the pan-European nature of blood cancer research infrastructure.

What sets them apart

MLL occupies a rare niche: a private SME that functions as a high-volume clinical reference laboratory for blood cancers while simultaneously contributing research-grade molecular data to EU consortia. Unlike university labs, they process real clinical patient samples at scale daily, giving them access to large, continuously growing datasets that are invaluable for big data and AI projects. For any consortium needing real-world hematological data, molecular diagnostics expertise, or a bridge between clinical practice and translational research, MLL is a strong and proven partner.

Highlights from their portfolio

• HARMONY
  Largest project by funding (EUR 299,753) and longest duration (2017-2023), building the foundational big data platform for hematological malignancies across Europe.
• INTERCEPT-MDS
  Represents MLL's most advanced scientific direction — single-cell sequencing and epigenetic analysis for intercepting myelodysplastic syndrome before progression to acute leukemia.
• GenoMed4ALL
  Marks MLL's entry into AI and federated learning for genomic medicine, combining their hematology expertise with computational approaches to personalized treatment.